Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rigel Pharmaceuticals has said its partner Merck Serono has begun enrolling patients in a phase I study evaluating the safety and tolerability of its multi-Aurora kinase inhibitor, for the treatment of hematological malignancies.
Subscribe to our email newsletter
This is the second of several phase I studies to be conducted in order to evaluate the safety and initial efficacy of the candidate R763 in different types of cancers, including solid tumors, hematological malignancies, and in combination with standard therapies.
Merck Serono licensed development and commercialization rights to R763 and Rigel's Aurora kinase program in October 2005.
This phase I study is designed to evaluate safety and tolerability at two different dosing regimens of the Aurora kinase inhibitor. Subjects with acute or chronic myeloid leukemia (AML or CML) or myelodysplastic syndrome (MDS) will be enrolled in each regimen and dosed orally with R763.
“R763 has shown encouraging results in in vitro and in vivo models of hematological malignancies where Aurora kinase is thought to play a role,” said Donald Payan, executive vice president of Rigel.